Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized study of ceftazidime-avibactam plus polymyxin B versus meropenem plus polymyxin B for carbapenem-resistant Enterobacteriaceae central nervous system infection
ChiCTR2000036914Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Oct 2020
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4 trial of ceftazidime + avibactam, polymyxin B and meropenem, sponsored by Huashan Hospital. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
ceftazidime + avibactampolymyxin Bmeropenem
Beyond the preview
Go deeper on ChiCTR2000036914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036914.